Mode
Text Size
Log in / Sign up
N/A N=116 Randomized Single-blind Diagnostic

VIdeo Telehealth in ALzheimer's: NeuroPsychology (VITAL-NP)

Suspected Typical Alzheimer's Disease (AD) · Suspected Atypical Alzheimer's Disease (AD)

Enrolled (actual)
116
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcome: Primary: Agreement of Cognitive Test Results Across Testing Modalities as Measured by Neuropsychological Test Mean Scores, Measures With Total Correct Items — 4.31; 4.40; 8.21; 8.60 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Face-to-face evaluation (FF) (Behavioral); TeleNP evaluation (Behavioral)
Age
Adult, Older Adult · 60+ yrs
Sex
All
Sponsor
University of Colorado, Denver
Primary completion
May 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Agreement of Cognitive Test Results Across Testing Modalities as Measured by Neuropsychological Test Mean Scores, Measures With Total Correct Items
4.31; 4.40; 8.21; 8.60; 12.40; 12.52
PRIMARY
Agreement of Neuropsychologist Diagnosis Across Testing Modalities as Measured by Neuropsychologist-Determined Diagnosis
0.74
PRIMARY
Agreement of Neuropsychologist Appraisal of Severity Across Testing Modalities as Measured by Neuropsychologist-Determined Severity
0.89
PRIMARY
Acceptability and Feasibility of Intervention Measures as Measured by 4-item Acceptability and Feasibility of Intervention Measures Scale
4.0; 3.95; 4.0; 4.0; 4.0; 4.0
PRIMARY
Acceptability and Feasibility of Intervention Measures as Measured by 19-item UTAUT Questionnaire Adapted to TeleNP
4.0; 4.0; 4.0
PRIMARY
Agreement of Cognitive Test Results Across Testing Modalities as Measured by Neuropsychological Test Mean Scores (Timed Measures)
104.84; 96.29; 88.54; 79.59

Summary

The overarching goal of this study is to a) assess the feasibility and preliminary validity of home-based delivery of TeleNP to patients with suspected Alzheimer's Disease (AD), referred for cognitive assessments in a Neurology Clinic; and b) elucidate whether TeleNP is equivalent to face-to-face evaluation (FF) for diagnostic adjudication of atypical versus typical AD.

Eligibility Criteria

Inclusion Criteria

  • Individuals age 60 to 90 years who are undergoing evaluation for possible AD and whose severity ranges from MCI to mild dementia.
  • Individuals must carry a diagnosis of either suspected typical AD or atypical AD, based on the referring neurologist's diagnosis.

Exclusion Criteria

  • Individuals with moderate to severe levels of dementia and individuals with active delirium (per neurologist's determination).
  • Individuals who are legally blind or deaf, due to the auditory and visual components of the study.
  • Individuals with a brain tumor and individuals who have a confirmed nonAD neurological diagnosis (e.g, Multiple Sclerosis; FTD).
  • Individuals who are being evaluated outside of the UCH Memory Disorders Clinic.
  • Individuals who report active (i.e., within the last 6 months) substance use of illicit drugs such as cocaine or methamphetamines, or who carry a diagnosis of a major psychiatric disorder (e.g., schizophrenia; bipolar disorder).

Note that care partners (3rd arm) did not undergo the intervention and there were no additional eligibility requirements for them except that they were involved in the patient's care

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05379023). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search